US EditionPoolbeg Pharma (AIM: POLB) Interim Results for the six months to 30 June 2025
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Poolbeg Pharma (AIM: POLB) Interim Results for the six months to 30 June 2025
Well-funded with multiple upcoming clinical milestones 29 September 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces itsRead More...
Poolbeg Pharma plc - Interim Results for the six months to 30 June 2025 - Optimum Strategic Communications
Well-funded with multiple upcoming clinical milestones 29 September 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces its unaudited interim results for the six months to 30 June 2025. Read more… The post Poolbeg Pharma plc – Interim Results for the six months to 30 June 2025 appeared first on Optimum Strategic Commu…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium